Cargando…
One-Year Outcomes of Preserflo(TM) MicroShunt Implantation versus Trabeculectomy for Pseudoexfoliation Glaucoma
This retrospective, single-center study evaluates the safety and efficacy of Preserflo(TM) MicroShunt (MicroShunt) implantations compared to trabeculectomies (TETs) in patients diagnosed with pseudoexfoliation glaucoma (PEXG). A total of 31 eyes from 28 patients received a MicroShunt implantation, a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141576/ https://www.ncbi.nlm.nih.gov/pubmed/37109334 http://dx.doi.org/10.3390/jcm12083000 |
_version_ | 1785033414396608512 |
---|---|
author | Nobl, Matthias Grün, Clara Kassumeh, Stefan Priglinger, Siegfried Mackert, Marc J. |
author_facet | Nobl, Matthias Grün, Clara Kassumeh, Stefan Priglinger, Siegfried Mackert, Marc J. |
author_sort | Nobl, Matthias |
collection | PubMed |
description | This retrospective, single-center study evaluates the safety and efficacy of Preserflo(TM) MicroShunt (MicroShunt) implantations compared to trabeculectomies (TETs) in patients diagnosed with pseudoexfoliation glaucoma (PEXG). A total of 31 eyes from 28 patients received a MicroShunt implantation, and 29 eyes from 26 patients received a TET. Surgical success was defined as an intraocular pressure (IOP) between 5 mmHg and 17 mmHg at the end of the follow-up period, no need for surgical revisions or secondary glaucoma surgery, and no loss of light perception. In the MicroShunt group, the mean IOP dropped from 20.8 ± 5.9 mmHg at baseline to 12.4 ± 2.8 mmHg (p < 0.0001) after one year. In the TET group, the mean IOP dropped from 22.3 ± 6.5 mmHg to 11.1 ± 3.7 mmHg (p < 0.0001) after 12 months. In both of the groups, the mean number of medications was reduced significantly (MicroShunt from 2.7 ± 1.2 to 0.2 ± 0.7; p < 0.0001 vs. TET from 2.9 ± 1.2 to 0.3 ± 0.9; p < 0.0001). Considering the success rates, 83.9% of the MicroShunt eyes achieved complete success, and 90.3% qualified for success at the end of the follow-up period. In the TET group, the rates were 82.8% and 93.1%, respectively. The postoperative complications were comparable between both groups. In conclusion, the MicroShunt implantation demonstrated non-inferiority regarding its efficacy and safety profile compared to TET in PEXG at a follow-up of one year. |
format | Online Article Text |
id | pubmed-10141576 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101415762023-04-29 One-Year Outcomes of Preserflo(TM) MicroShunt Implantation versus Trabeculectomy for Pseudoexfoliation Glaucoma Nobl, Matthias Grün, Clara Kassumeh, Stefan Priglinger, Siegfried Mackert, Marc J. J Clin Med Article This retrospective, single-center study evaluates the safety and efficacy of Preserflo(TM) MicroShunt (MicroShunt) implantations compared to trabeculectomies (TETs) in patients diagnosed with pseudoexfoliation glaucoma (PEXG). A total of 31 eyes from 28 patients received a MicroShunt implantation, and 29 eyes from 26 patients received a TET. Surgical success was defined as an intraocular pressure (IOP) between 5 mmHg and 17 mmHg at the end of the follow-up period, no need for surgical revisions or secondary glaucoma surgery, and no loss of light perception. In the MicroShunt group, the mean IOP dropped from 20.8 ± 5.9 mmHg at baseline to 12.4 ± 2.8 mmHg (p < 0.0001) after one year. In the TET group, the mean IOP dropped from 22.3 ± 6.5 mmHg to 11.1 ± 3.7 mmHg (p < 0.0001) after 12 months. In both of the groups, the mean number of medications was reduced significantly (MicroShunt from 2.7 ± 1.2 to 0.2 ± 0.7; p < 0.0001 vs. TET from 2.9 ± 1.2 to 0.3 ± 0.9; p < 0.0001). Considering the success rates, 83.9% of the MicroShunt eyes achieved complete success, and 90.3% qualified for success at the end of the follow-up period. In the TET group, the rates were 82.8% and 93.1%, respectively. The postoperative complications were comparable between both groups. In conclusion, the MicroShunt implantation demonstrated non-inferiority regarding its efficacy and safety profile compared to TET in PEXG at a follow-up of one year. MDPI 2023-04-20 /pmc/articles/PMC10141576/ /pubmed/37109334 http://dx.doi.org/10.3390/jcm12083000 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nobl, Matthias Grün, Clara Kassumeh, Stefan Priglinger, Siegfried Mackert, Marc J. One-Year Outcomes of Preserflo(TM) MicroShunt Implantation versus Trabeculectomy for Pseudoexfoliation Glaucoma |
title | One-Year Outcomes of Preserflo(TM) MicroShunt Implantation versus Trabeculectomy for Pseudoexfoliation Glaucoma |
title_full | One-Year Outcomes of Preserflo(TM) MicroShunt Implantation versus Trabeculectomy for Pseudoexfoliation Glaucoma |
title_fullStr | One-Year Outcomes of Preserflo(TM) MicroShunt Implantation versus Trabeculectomy for Pseudoexfoliation Glaucoma |
title_full_unstemmed | One-Year Outcomes of Preserflo(TM) MicroShunt Implantation versus Trabeculectomy for Pseudoexfoliation Glaucoma |
title_short | One-Year Outcomes of Preserflo(TM) MicroShunt Implantation versus Trabeculectomy for Pseudoexfoliation Glaucoma |
title_sort | one-year outcomes of preserflo(tm) microshunt implantation versus trabeculectomy for pseudoexfoliation glaucoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10141576/ https://www.ncbi.nlm.nih.gov/pubmed/37109334 http://dx.doi.org/10.3390/jcm12083000 |
work_keys_str_mv | AT noblmatthias oneyearoutcomesofpreserflotmmicroshuntimplantationversustrabeculectomyforpseudoexfoliationglaucoma AT grunclara oneyearoutcomesofpreserflotmmicroshuntimplantationversustrabeculectomyforpseudoexfoliationglaucoma AT kassumehstefan oneyearoutcomesofpreserflotmmicroshuntimplantationversustrabeculectomyforpseudoexfoliationglaucoma AT priglingersiegfried oneyearoutcomesofpreserflotmmicroshuntimplantationversustrabeculectomyforpseudoexfoliationglaucoma AT mackertmarcj oneyearoutcomesofpreserflotmmicroshuntimplantationversustrabeculectomyforpseudoexfoliationglaucoma |